DesmoMelt®: Product characteristics

DesmoMelt is a sublingual oral lyophilisate formulation of desmopressin which quickly dissolves when taken.1,2 It is indicated for the treatment of primary nocturnal enuresis (PNE) in children and adults aged 5 to 65.1

DesmoMelt is well accepted by children of various ages and facilitates early intervention,2 providing an effective and convenient solution to PNE and helping children and families return to a normal life.

Children aged 5–11 years prefer DesmoMelt to tablets2

A statistically significant preference for DesmoMelt has been shown in children aged 5–11 years.2  (For patients <12 years, 60.6% patients  preferred the melt formulation [p=0.009])2

  • DesmoMelt dissolves under the tongue, removing the difficulty children may face swallowing a tablet2
  • High compliance is associated with DesmoMelt; 94.5% of patients showed ≥80% compliance during a six-week long study2

DesmoMelt provides a superior and longer duration of action 3–8 hours after dosing3

Compared with tablets, DesmoMelt provides a significantly superior antidiuretic effect and concentrating capacity 3–8 hours after dosing.3


O Outliers with desmopressin melt

ø Outliers with desmopressin tablet

Due to the superior pharmacodynamic characteristics of the melt formulation, more than 25% of patients had a higher diuresis rate with the tablet vs. melt formulation.3 Patients with the melt formulation produced less urine over the same time period (results based on urine collected in the plateau phase at hours 3–5 [p<0.02], and in action at hours 5–8 [p<0.005]).3

Switching from tablet to DesmoMelt is associated with increased efficacy and compliance4

The probability of a reduction in bedwetting episodes is twice as likely with DesmoMelt4

  • One study shows a two-fold likelihood that a child will experience a dry night when taking desmopressin melt over tablet.4 This suggests a clinical benefit for switching to the sublingual formulation.4

Fluid intake is not required with drug administration2

Tablet consumption may require 60 mL of water (approximately a quarter of the expected bladder capacity of a 7 year old) which may also impact the efficacy of desmopressin.4

  • De Guchtenaere, et al. suggest that the melt formulation could cause a 72 mL reduction in urine during the studied time interval; this in turn, might mean the difference between waking up wet or dry3

A single dose (120mcg) of DesmoMelt should be taken before bedtime for a period of 3 months, followed by a one-week drug-free period to assess results. If symptoms persist, the treatment cycle should be repeated.1

  • If needed, the dose taken can be increased to 240mcg1

For more information about the benefits of DesmoMelt, download our short leaflet.

 

Prescribing Information and Adverse Event Reporting

DesmoMelt prescribing information can be downloaded here. Alternatively the SmPC can be accessed via the EMC website.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Ferring Pharmaceuticals Ltd.

Tel: 0844 931 0050, Email: medical@ferring.com

Are you a Health Care Professional?

The following information is intended for UK Healthcare Professionals (HCPs). It contains information about prescribing, plus relevant patient information.

UY/2407/2017/UK September 2017